We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Enriched FAK Activity Protects Cardiomyocytes from Heart Attack Damage

By LabMedica International staff writers
Posted on 22 Mar 2012
Cardiovascular disease researchers have identified a protein in cardiomyocytes that when expressed at high levels protects heart cells from damage caused during myocardial infarction due to the sudden loss of oxygen.

Investigators at the University of North Carolina (Chapel Hill, USA) had shown previously that deletion of the enzyme focal adhesion kinase (FAK) exacerbated myocyte death following heart attack. More...
FAK is a highly conserved, cytosolic, protein-tyrosine kinase involved in cell-cell and cell-matrix interaction and responsible for formation of the focal adhesion complex. It is widely expressed throughout development.

In the current study, the investigators examined the effect of enriched FAK activity on cardiomyocytes during and after heart attack (ischemia/perfusion) in a mouse model. To this end, they created a line of mice genetically engineered to express a highly active form of FAK (SuperFAK) in their cardiomyocytes.

They reported in the March 1, 2012, online edition of the journal Arteriosclerosis, Thrombosis and Vascular Biology that FAK activity in unstressed transgenic hearts was modestly elevated, but this had no discernible effect on anabolic heart growth or cardiac function. On the other hand, SuperFAK hearts exhibited a dramatic increase in FAK activity and a reduction in myocyte apoptosis and infarct size 24 to 72 hours following ischemia/perfusion.

Mechanistic studies revealed that elevated FAK activity protected cardiomyocytes from ischemia/perfusion-induced apoptosis by enhancing nuclear factor-kappaB (NF-kappaB)-dependent survival signaling during the early period of reperfusion (30 and 60 minutes). Moreover, adenoviral-mediated expression of SuperFAK in cultured cardiomyocytes attenuated H2O2 or hypoxia/reoxygenation-induced apoptosis. Blockade of the NF-kappaB pathway using a pharmacological inhibitor or small interfering RNAs completely abolished the beneficial effect of SuperFAK.

"This study shows that we can enhance existing cell survival pathways to protect heart cells during a heart attack," said senior author Dr. Joan Taylor, associate professor of pathology and laboratory medicine at the University of North Carolina. "We thought if we could activate FAK to a greater extent, then we could better protect those heart cells."

"I think folks could use this idea to exploit mutations in other molecules - by thinking about how to modify the protein so that it can be under natural controls," said Dr. Taylor. "Negative feedback loops are important because they "reset" the system."

Related Links:

University of North Carolina


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Gold Member
Platelet Function Analyzer
PL-12
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.